Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2)
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorDuke University
About this trial
IRIS-CKD is a two-program implementation study to improve guideline-recommended screening and treatment of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Eligibility criteria
Qualifiers
(CKD Management)
Adults with type 2 diabetes (T2D)
Receiving primary care within the healthcare system, visit within 24 months (any PCP provider, including APP)
UACR >300 mg/g or
Disqualifiers
(CKD Management)
Type 1 diabetes
Most recent eGFR <20 ml/min/1.73 m2
Prior kidney transplant
Trial design
Treatments tested in this trial
- (IRIS-CKD Management Program): Education
- (IRIS-CKD Management Program): GDMT
Treatment groups
420 Participants
are divided into 2 treatment groupsLocations
7Alabama
University of Alabama35233, Birmingham United States
Florida
Orlando Health33701, St. Petersburg United States
Michigan
University of Michigan48109, Ann Arbor United States
Minnesota
Essentia Institute of Rural Health55805, Duluth United States
Sponsors and collaborators
Duke University
Lead sponsor
Bayer
Collaborator
Boehringer Ingelheim
Collaborator
Eli Lilly and Company
Collaborator
Source ClinicalTrials.gov